Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 125.66 Delayed Data As of 3:59pm ET |  +2.64 / +2.15%Today’s Change | 84.97 Today|||52-Week Range 167.33 | +9.11% Year-to-Date |
Latest ALNY News | Press Releases
| Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease Nov 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 123.02 |
| Today’s open | 125.05 |
| Day’s range | 123.33 - 127.91 |
| Volume | 24,013 |
| Average volume (3 months) | 505,606 |
| Market cap | $14.5B |
Data as of 3:59pm ET, 11/24/2020
Growth & Valuation
| Earnings growth (last year) | -7.13% |
| Earnings growth (this year) | +12.98% |
| Earnings growth (next 5 years) | +89.28% |
| Revenue growth (last year) | +193.36% |
| P/E ratio | NM |
| Price/Sales | 57.26 |
| Price/Book | 9.72 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | -1.02 | -1.46% |
| ---- | ||
| CTLTCatalent Inc | -5.15 | -5.16% |
| MRTXMirati Therapeutics ... | -1.97 | -0.88% |
Data as of 4:00pm ET, 11/24/2020
Financials
| Next reporting date | February 11, 2021 |
| EPS forecast (this quarter) | -$1.72 |
| Annual revenue (last year) | $219.8M |
| Annual profit (last year) | -$886.1M |
| Net profit margin | -403.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
